Trial Profile
RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary) ; Sirolimus
- Indications Coronary arteriosclerosis
- Focus Therapeutic Use
- Acronyms RECOVERY
- Sponsors OrbusNeich
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2017 Results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
- 23 Oct 2017 According to an OrbusNeich media release, data will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT).